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5 and positively regulates CYP51A1 and CYP61A1 which catalyze sterol biosynthesis, and knockdown of endogenous PGRMC1 in HEK293 cells resulted in the decreased cholesterol synthesis catalyzed by human CYP51A1. Thus, it has been demonstrated that PGRMC1 positively regulates P450-mediated sterol or steroid syntheses, making it "a helping hand for P450 proteins" (Debose-Boyd, 2007) .
In contrast to endobiotic-metabolizing P450s, there is limited information on the effects of PGRMC1 on xenobiotic-metabolizing P450s. Although it was shown, by co-immunoprecipitation using a co-expression system in HEK293 cells, that PGRMC1 bound to CYP3A4 (Hughes et al., 2007) , the functional significance remains to be clarified. In this study, we sought to investigate whether PGRMC1 might be a regulator of human drug-metabolizing P450 activities, focusing on CYP3A4, CYP2C9 and CYP2E1.
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Materials and Methods
Chemicals and Reagents. Testosterone was purchased from Wako Pure Chemical Industries (Osaka, Japan). 7-Ethoxycoumarin, 7-hydroxycoumarin, chlorzoxazone, 6-hydroxychlrozoxazone, diclofenac, and S-warfarin were from Sigma-Aldrich (St. Louis, MO). 4'-Hydroxydiclofenac, 6β-hydroxytestosterone, and 7-hydroxywarfarin were purchased from BD Gentest (Woburn, MA), Steraloids (Wilton, NH), and Ultrafine Chemicals (Manchester, UK), respectively. Midazolam and 1'-hydroxymidazolam were kindly provided by Astellas Pharmaceutical (Tokyo, Japan). Clonazepam was kindly provided by Roche (Basel, Switzerland) . NADP + , glucose-6-phosphate and glucose-6-phosphate dehydrogenase were from Oriental Yeast (Tokyo, Japan). Adenovirus Expression Vector kit (Dual Version) and QuickTiter Adenovirus Titer Immunoassay kit were from Takara (Osaka, Japan) and Cell Biolabs (Tokyo, Japan), respectively. The pTARGET vector was purchased from Promega (Madison, WI). Lipofectamine 2000 was from Invitrogen (Carlsbad, CA). All primers were commercially synthesized at Hokkaido System Science (Sapporo, Japan). Rabbit anti-human CYP3A4 polyclonal antibody and rabbit anti-human CYP2C9 antibody were from BD Gentest.
Goat anti-rat CYP2E1 polyclonal antibody was from Nosan (Yokohama, Japan). Rabbit anti-human PGRMC1 polyclonal antibody and mouse anti-FLAG monoclonal antibody (M2)
were from Sigma-Aldrich. Rabbit anti-human/rat CPR antibody was from CHEMICON (Temecula, CA). Rabbit anti-cytochrome b 5 antibody and mouse anti-c-Myc monoclonal antibody (9E10) were from Santa Cruz Biotechnology (Santa Cruz, CA). Alexa Fluor 680 donkey anti-goat IgG was from Invitrogen. IRDye 680 goat anti-rabbit IgG and goat anti-mouse IgG were from LI-COR Biosciences (Lincoln, NE). All other chemicals and solvents were of the highest grade commercially available.
Construction of Recombinant Adenoviruses and Plasmids. Recombinant adenoviruses
expressing CYP3A4 (AdCYP3A4), CYP2C9 (AdCYP2C9), and green fluorescence protein (AdGFP) were constructed as in our previous studies (Hosomi et al., 2010; Iwamura et al., This article has not been copyedited and formatted. The final version may differ from this version. (AdCYP2E1) were created as follows. A fragment containing the full-length coding region of the human PGRMC1 or CYP2E1 cDNA was amplified by PCR using the primer pairs shown in Table 1 with a human liver cDNA as a template. The fragments were subcloned into the pAxCAwtit vector at a Swa I site. These vectors and the adenovirus genome DNA-terminal protein complex were co-transfected into HEK293 cells by Lipofectoamine 2000. The recombinant adenovirus was isolated and propagated. Viral titers were determined using the QuickTiter Adenovirus Titer Immunoassay kit. The multiplicity of infection (MOI) was defined as the ratio of infectious units divided by the number of cells.
Expression vector for human PGRMC1 containing FLAG tag at the C-terminus (FLAG-PGRMC1) was constructed as follows. Human PGRMC1 cDNA was amplified by PCR using the primers S-PGRMC1 and AS-FLAG PGRMC1 (Table 1) with the human liver cDNA as a template. The AS-FLAG PGRMC1 primer contains complementary sequences of FLAG tag and a stop codon. The PCR product was digested with BamH I and Xho I and ligated into the pcDNA3.1 Hygro+ vector (Invitrogen).
Expression vectors for human P450s (CYP3A4, CYP2C9, and CYP2E1) containing 3×Myc tag at the C-terminus (Myc-P450) were constructed as follows. Once P450 cDNA lacking a stop codon was amplified by PCR with the primer pairs shown in Table 1 , it was digested with Xho I and Kpn I and subcloned into the pTARGET vector digested with the same restriction enzymes (pTARGET/P450 stop-). A double strand DNA fragment containing three tandem copies of Myc tag sequence followed by a stop codon (Table 1) supplemented with 0.1 mM non-essential amino acid (NEAA) (Invitrogen) and 10% fetal bovine serum (FBS) (Invitrogen). For the construction of the co-expression systems for FLAG-PGRMC1 and Myc-P450, the HEK293 cells were cultured in DMEM containing 4.5 g/liter glucose, 10 mM HEPES, and 10% FBS. Human cryopreserved hepatocytes, lot H704 (Caucasian, female, 49 years old), were purchased from XenoTech (Lenexa, KS). The hepatocytes were cultured in hepatocyte culture medium (HCM) (Cambrex, East Rutherford, NJ) on a plate coated with Cell Matrix Type I-C (Nitta Gelatin, Tokyo, Japan). These cells were maintained at 37°C under an atmosphere of 5% CO 2 , 95% air.
Infection of Recombinant Adenoviruses to HepG2 Cells or Cryopreserved Human
Hepatocytes. HepG2 cells were seeded at 7.5 × 10 5 cells/well into a 6-well plate and were allowed to grow confluent. The cells were infected with a constant MOI of AdCYP (AdCYP3A4: 5, AdCYP2C9: 20, AdCYP2E1: 25, represented as ×1 in Fig. 1 ) and varied MOI of AdPGRMC1 (0, 2.5, 5, 10, represented as 0, ×1, ×2, ×4). To make the total MOI the same value in four different experimental conditions, AdGFP was infected. After 24 h, the cultured medium was replaced with fresh medium without adenovirus. After 48 h, total cell homogenates were prepared by homogenization with TGE buffer (10 mM Tris-HCl (pH 7.4), 20% glycerol, and 0.1 mM EDTA). The protein concentration was determined using Bradford protein assay reagent (Bio-Rad, Hercules, CA) with γ-globulin as a standard.
The human hepatocytes were seeded at 1.5 × 10 6 cells/well into a 6-well plate. After 3 h, the medium was changed to HCM (albumin-and antibiotics-free) containing AdPGRMC1 or AdGFP at MOI 30. After 1 h, the medium was replaced with fresh HCM. After 48 h, the total cell homogenates were prepared as described above. were prepared according to the method described previously (Tabata et al., 2004) . MgCl 2 and 1 unit/mL glucose 6-phosphate dehydrogenase) and each substrate. The reaction mixture was preincubated at 37°C for 2 min and the reaction was started by adding the NADPH-generating system.
SDS-PAGE and
The testosterone 6β-hydroxylase activity was determined as described previously (Nakajima et al., 1999 ) with a 20-min reaction time. The product formation was determined using HPLC with a LachromUltra C18 (4.6 × 100 mm; 3 µm) column (HITACHI, Tokyo, Japan) and monitored at 240 nm.
The midazolam 1'-hydroxylase activity was determined as described previously (Kronbach et al., 1989) with slight modifications. The reaction mixture was incubated at 37°C for 15 min and the reaction was terminated by adding 100 µL of ice-cold methanol. Clonazepam (20 ng) was added as an internal standard. After the removal of the protein by centrifugation at 10,000 g for 5 min, a 20 µL-portion of the sample was subjected to liquid chromatography-tandem mass B to 90% B over 2 to 3 min followed by 90% B for 7 min and then the column was allowed to re-equilibrate at the initial conditions for 4 min. The LC was connected to a PE Sciex API 2000 tandem mass spectrometer (AB SCIEX) operated in the positive electrospray ionization mode.
The turbo gas was maintained at 550°C. Nitrogen was used as the nebulizing gas, turbo gas, and curtain gas at 40, 90, and 40 psi, respectively. Parent and/or fragment ions were filtered in the first quadrupole and dissociated in the collision cell using nitrogen as the collision gas. The S-warfarin 7-hydroxylase activity was determined as described previously (Yamazaki et al., 1997 ) with a 20-min incubation time. The product formation was determined using HPLC with a Mightysil RP-18 (4.6 × 150 mm; 5 µm) column (Kanto Chemical, Tokyo, Japan) and monitored with the excitation wavelength set at 320 nm and emission at 415 nm.
The diclofenac 4'-hydroxylase activity was determined by the method by Katoh et al. (2004) with a 30-min incubation time. The product formation was determined using HPLC with a TSK-GEL ODS-80T M (4.6 × 250 mm; 5 µm) column (TOSOH, Tokyo, Japan) and monitored at 280 nm.
The chlorzoxazone 6-hydroxylase activity was determined as described previously (Mohri et al., 2010 ) with a 30-min incubation time. The product formation was determined using HPLC with a LachromUltra C18 (4.6 × 100 mm; 3 µm) column and monitored at 295 nm.
The 7-ethoxycoumarin O-deethylase activity was determined as described previously (Yamazaki et al., 1999 ) with a 30-min incubation time. The product formation was determined This article has not been copyedited and formatted. The final version may differ from this version. using HPLC with a Mightysil RP-18 (4.6 × 150 mm; 5 µm) column and monitored with the excitation wavelength set at 338 nm and emission at 458 nm.
Kinetic parameters were estimated from the fitted curve using a computer program (KaleidaGraph, Synergy Software, Reading, PA) designed for nonlinear regression analysis.
The following equations were used:
where V is the velocity of the reaction, [S] is the substrate concentration, K m is the Michaelis-Menten constant, V max is the maximum velocity, and K i is the substrate inhibition constant. Data are expressed as the means ± SD of three independent determinations.
Co-immunoprecipitation Assay. The FLAG-PGRMC1 and each Myc-P450 expression plasmid were transiently co-transfected into HEK293 cells. Briefly, the day before transfection, the cells were seeded into a 6-well plate coated with Cell Matrix Type I-C. After 24 h, each 2 µg of FLAG-PGRMC1 and Myc-P450 plasmids were transfected using Lipofectamine 2000. After 48 h, the cells were collected and total cell homogenates were prepared by homogenization with TGE buffer. Five-hundred micrograms of protein were suspended in either buffer A or buffer B in a final volume 0.5 mL and rotated at 4°C for 2 h. Buffer A consisted of 0.5% Nonidet P-40, 0.25% sodium deoxycholate, 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 0.5 mM (p-amidinophenyl)-methanesulfonyl fluoride hydrochloride, 2 μg/mL aprotinin, and 2 μg/mL leupeptin. The detergents in buffer A were replaced with 0.1% digitonin in buffer B. The lysates were centrifuged at 100,000 g for 30 min. To the supernatants, the anti-FLAG antibody was added and incubated for 8 h followed by precipitation with protein G sepharose beads. The beads were washed with buffer A or B and suspended with Laemmli sample buffer.
The eluent was subjected to Western blot analyses with anti-FLAG antibody or anti-c-Myc antibody.
Statistical Analyses. Statistical significance was determined by using unpaired, two-tailed
This article has not been copyedited and formatted. The final version may differ from this version. MOIs to obtain the expression levels of PGRMC1 and P450s that are close to those in pooled human liver microsomes. When AdPGRMC1 was infected at MOI 3-4, the expressed PGRMC1 levels were close to those in the pooled HLM. Accordingly, we set the MOIs for AdPGRMC1 at 2.5, 5, and 10, which were represented as ×1, ×2, and ×4, respectively) ( Fig. 1 ).
The MOIs for AdCYP2C9 and AdCYP2E1 were set at 20 and 25, respectively. In the case of AdCYP3A4, MOIs over 10 showed cellular toxicity. Therefore, we set the MOIs for AdCYP3A4 at 5, although the level of CYP3A4 protein produced was lower than that in the pooled HLM ( Fig. 1) but was in the range of those in individual HLM, as described below. Thus, we obtained four lines for each P450 with various levels of PGRMC1. Using these systems, we investigated the effects of PGRMC1 on the P450 activities.
Effects of Co-expression of PGRMC1 on CYP3A4 Activities. To investigate the effects of PGRMC1 on the CYP3A4 activity, kinetic analyses of testosterone 6β-hydroxylation and midazolam 1'-hydroxylation were performed using the total cell homogenates from the HepG2 co-expression system. The kinetics of testosterone 6β-hydroxylation followed the Michaelis-Menten equation (Fig. 2A) . The K m , V max , and V max /K m values of the homogenates from the cells with no exogenous PGRMC1 were 56.9 ± 9.1 µM, 54.3 ± 4.0 pmol/min/pmol CYP, and 0.96 ± 0.08 µL/min/pmol CYP, respectively ( Table 2 ). The co-expression of PGRMC1 significantly decreased the V max values and increased the K m values, resulting in a decrease of the V max /K m values in a PGRMC1 concentration-dependent manner. The kinetics of midazolam 1'-hydroxylation followed the substrate-inhibition equation (Fig. 2B ). The K m , V max , K i , and V max /K m values by the homogenates from the cells with no exogenous PGRMC1 were 5.7 ± 0.9 µM, 9.8 ± 1.5 pmol/min/pmol CYP, 15.9 ± 4.1 µM, and 1.72 ± 0.03 µL/min/pmol CYP, This article has not been copyedited and formatted. The final version may differ from this version. Effects of Co-expression of PGRMC1 on CYP2C9 Activities. To investigate the effects of PGRMC1 on the CYP2C9 activity, kinetic analyses of S-warfarin 7-hydroxylation and diclofenac 4'-hydroxylation were performed. The kinetics of S-warfarin 7-hydroxylation followed the Michaelis-Menten equation (Fig. 3A) . The K m , V max , and V max /K m values by the homogenates from the cells with no exogenous PGRMC1 were 1.6 ± 0.1 µM, 5.4 ± 0.2 pmol/min/pmol CYP, and 3.3 ± 0.2 µL/min/pmol CYP, respectively (Table 3) . The co-expression of PGRMC1 significantly decreased the V max values in a PGRMC1
concentration-dependent manner but did not affect the K m values, resulting in a decrease of the V max /K m values. The kinetics of diclofenac 4'-hydroxylation followed the Michaelis-Menten equation (Fig. 3B ). The K m and V max , and V max /K m values by the homogenates from the cells with no exogenous PGRMC1 were 7.3 ± 0.3 µM, 91.6 ± 6.8 pmol/min/pmol CYP, and 12.6 ± 1.5 µL/min/pmol CYP, respectively (Table 3) . The co-expression of PGRMC1 significantly decreased the V max values in a PGRMC1 concentration-dependent manner but did not affect the K m values, resulting in a decrease of the V max /K m values. Thus, it was demonstrated that PGRMC1 has the ability to attenuate the CYP2C9 activity independently of the substrate.
Effects of Co-expression of PGRMC1 on CYP2E1 Activities. To investigate the effects of PGRMC1 on the CYP2E1 activity, kinetic analyses of chlorzoxazone 6-hydroxylation and 7-ethoxycoumarin O-deethylation were performed. The kinetics of chlorzoxazone 6-hydroxylation followed the Michaelis-Menten equation (Fig. 4A) . The K m , V max , and V max /K m values by the homogenates from the cells with no exogenous PGRMC1 were 67.1 ± 5.6 µM, 618.3 ± 18.2 pmol/min/pmol CYP, and 9.3 ± 0.5 µL/min/pmol CYP, respectively (Table 4) 
Effects of Overexpression of PGRMC1 on Enzyme Activities in Human Hepatocytes.
To investigate whether PGRMC1 modulates the activities of endogenous human P450s, we sought to overexpress PGRMC1 in human hepatocytes. When the homogenates from the human hepatocytes were subjected to Western blot analysis, the band density of PGRMC1
protein was similar to that in the pooled HLM (Fig. 5A ). When AdPGRMC1 was infected, the PGRMC1 protein level was significantly (5.6 fold, P < 0.001) increased (Fig. 5A ). We confirmed that there was no morphological change by the infection with AdPGRMC1. Using the homogenates from these cells, the midazolam 1'-hydroxylase, S-warfarin 7-hydroxylase, and chlorzoxazone 6-hydroxylase activities, at the substrate concentrations of 10, 10, and 500 µM, respectively, were evaluated. Interestingly, we found that the midazolam 1'-hydroxylase and S-warfarin 7-hydrozylase activities in the homogenates from the AdPGRMC1-infected cells were significantly lower than those in control (AdGFP-infected cells). In contrast, the chlorzoxazone 6-hydroxylase activity was not affected by the overexpression of PGRMC1 (Fig.   5B ). These results suggest that PGRMC1 modulates the endogenous human P450 activity in an isoform-specific manner, supporting the results from the expression systems. systems to perform the immunoprecipitation assay using anti-tag antibodies. We confirmed, by
Western blot analyses using anti-FLAG and anti-c-Myc antibodies, that both FLAG-PGRMC1
and Myc-P450s were successfully expressed (Fig. 6 ). When the lysates using buffer A were assayed, the PGRMC1 in the three expression systems was immunoprecipitated to the same extent by using the anti-FLAG antibody, and only Myc-CYP2E1 was co-immunoprecipitated (Fig. 6A) . When the lysates using buffer B were assayed, all three P450s were co-immunoprecipitated (Fig. 6B) . These results suggest that PGRMC1 binds directly to these P450s, although the degree would be different among the isoforms. (Table 5) . Although the variability of the CYP3A4 protein levels was large (3 to 72 pmol/mg, 24-fold), those of the CYP2C9 (5 to 17 pmol/mg, ~3-fold) and the CYP2E1 (3 to 16 pmol/mg, ~5-fold) protein levels were relatively small. As shown in supplemental Fig. 1A -C, the midazolam 1'-hydroxylase, S-warfarin 7-hydroxylase, and chlorzoxazone 6-hydroxylase activities represented as the metabolite/min/mg protein were significantly correlated with CYP3A4, CYP2C9, and CYP2E1, respectively. To investigate whether the PGRMC1 would be a factor modulating the P450 activities, correlation analyses between the ratio of PGRMC1 to P450 and the midazolam 1'-hydroxylase, S-warfarin 7-hydroxylase, and chlorzoxazone 6-hydroxylase activities represented as the metabolite/min/pmol CYP were performed. We expected inverse correlations between the PGRMC1/CYP3A4 ratio and midazolam 1'-hydroxylase or PGRMC1/CYP2C9 ratio and S-warfarin 7-hydroxylase activities based on the results of the co-expression systems in HepG2 cells. However, no inverse correlation was observed (Supplemental Fig. 1D-F) . Additionally, except for the CPR/CYP2E1 ratio, the This article has not been copyedited and formatted. The final version may differ from this version. Fig. 1G-L) . Next, we determined the relationship between the PGRMC1 protein level and each P450 activity corrected with the CPR protein (Supplemental Fig. 2A -C) or cytochrome b 5 protein (Supplemental Fig. 2D-F ) levels. However, no inverse correlation was observed in the CYP3A4 or CYP2C9 activities. Since the PGRMC1 protein levels were significantly correlated with the CPR (R = 0.50, P < 0.01) and cytochrome b 5 (R = 0.76, P < 0.0001) protein levels (Supplemental Fig. 2G-H) , it would be difficult to estimate the contribution of PGRMC1 to the P450 activities in HLM by the correlation analyses.
Discussion
In this study, we investigate the effects of PGRMC1 on the human drug-metabolizing P450 activities, focusing on three major isoforms, CYP3A4, CYP2C9, and CYP2E1. Using co-expression systems for PGRMC1/CYPs in HepG2 cells, we found that PGRMC1 increased the K m and decreased the V max of the CYP3A4 activities, and decreased the V max of the CYP2C9 activities irrespective of the substrates (Figs. 2 and 3) . In contrast to CYP3A4 and CYP2C9, PGRMC1 did not dramatically affect the CYP2E1 activities, indicating the effects of PGRMC1
would be P450 isoform-dependent. During the process of preparing this report, an independent study reported that PGRMC1 commonly decreased the CYP3A4, CYP2C8 and rabbit CYP2C2 activities using co-expression systems in HEK293 cells (Szczesna-Skorupa and Kemper, 2011).
They evaluated the enzyme activities by P450-Glo assay at a substrate concentration. The findings that PGRMC1 decreased the activities of drug-metabolizing P450s were similar between our and recent reports, but our new findings are that the effects of PGRMC1 on the kinetics were different between the P450 isoforms and that there exists P450(s) not affected by PGRMC1. When we mixed the homogenates from the single expression system for PGRMC1 and the homogenates from the single expression system for P450s, no changes were observed in the kinetics of each P450 activity (data not shown). Therefore, it was suggested that co-localization on the membrane would be critical for PGRMC1 to exert its effect in modulating the P450s activities. It has been reported that PGRMC1 is predominantly located in the endoplasmic reticulum. However, in a human ovarian cancer cell line, Ovcar-3, PGRMC1 is found in the cytoplasm . To analyze the localization of PGRMC1 in human liver, we performed Western blot analysis using cytosol, but PGRMC1 could not be detected.
Therefore, the subcellular localization of PGRMC1 appears to be cell type-specific.
To investigate whether PGRMC1 modulates the activities of endogenous P450, we performed experiments using human hepatocytes. First, we sought to investigate the effects of repression of PGRMC1 by siRNA on the P450 activities (data not shown). When siRNA for PGRMC1 (Stealth select RNAi, Invitrogen) was transfected into human hepatocytes, the PGRMC1 mRNA levels were decreased by 70%. However, the PGRMC1 protein level was not not CYP2E1 activity, which were the same as with the HepG2 co-expression systems (Fig. 5) .
These results suggest that PGRMC1 modulates the activities of endogenous P450 in an isoform-specific manner.
Using the co-immunoprecipitation assay (Fig. 6) , we found that PGRMC1 interacts with P450s (not only CYP3A4 and CYP2C9 but also CYP2E1). When buffer A containing Nonidet P-40 and sodium deoxycholate, which are relatively strong detergents, was used, only CYP2E1 was co-immunoprecipitated ( Fig. 6A) . However, when buffer B containing digitonin, which is a relatively weaker detergent, was used, all of the three P450 isoforms were co-immunoprecipitated (Fig. 6B) . These results suggested that the binding of PGRMC1 to CYP2E1 might be stronger than the binding to CYP3A4 or CYP2C9. Alternatively, the number of CYP2E1 molecules that bound to a PGRMC1 molecule might be larger than that of CYP3A4 or CYP2C9. In other words, a smaller number of PGRMC1 molecules may bind to CYP2E1.
Such differences might explain why PGRMC1 did not affect the CYP2E1 activity but decreased the CYP3A4 and CYP2C9 activities, or the effects of PGRMC1 might not be a simple protein-protein interaction.
It was demonstrated that introduction of a mutation in the cytochrome b 5 -like domain of PGRMC1, to which heme binds, abolishes the binding to CYP7A1 (Mansouri et al., 2008 was observed, they concluded that PGRMC1 binds to CPR and decreases the P450 activities. In contrast to their study, the co-immunoprecipitation of CPR and PGRMC1 was not observed in our system using HEK293 cells without the overexpression of CPR, probably due to the low expression level (data not shown). Alternatively, we measured the cytochrome c reduction and found that PGRMC1 did not alter the CPR activity (Supplemental Table 1 ). Thus, the decrease of the P450 activities by PGRMC1 might not be due to the decrease of CPR activity, although the possibility that PGRMC1 might influence the electron transferring from CPR to P450, because the V max values of CYP3A4 and CYP2C9 were decreased, could not be excluded. In the case of CYP3A4, an increase of the K m values was also observed. Therefore, as another mechanism, it is suggested that PGRMC1 might cause an allosteric change in the CYP3A4 structure that affects the affinity to substrates. Nevertheless, the effects of PGRMC1 on the P450 activity were diverse depending on the P450 isoforms, and further detailed studies are needed to clarify the underlying mechanisms.
In this study, the variability of the PGRMC1 protein levels in HLM was first evaluated. In 29 human liver samples, there was 5-fold variability (Table 5) . We sought to estimate the contribution of PGRMC1 to the modulation of the P450 activities by correlation analyses between the P450 activities and P450 or PGRMC1 protein levels. In the analysis, we took into account the other components, the transferring of electrons to P450 such as CPR or cytochrome b 5 . Although these components positively regulate the enzyme activities of CYP3A4, CYP2C9, and CYP2E1, no clear correlation with the P450 activities was observed except in the case of CYP2E1. It has been reported that the molar ratio of P450:CPR:cytochrome b 5 seems to be important to understanding the role of CPR in the modulation of the P450 activities. We can determine the absolute expression levels of P450, CPR, and cytochrome b 5 , but not PGRMC1.
Understanding the absolute expression level of PGRMC1 in HLM would be helpful to determine the relative importance of PGRMC1 in the modulation of the P450 activity.
Earlier studies reported that PGRMC1 increased the activities of CYP21A2 and CYP51A1 that are responsible for steroid or sterol metabolism (Min et al., 2005; Hughes et al., 2007) . In contrast, this study found that PGRMC1 decreased the activity of human drug-metabolizing P450s, which is supported by the study by Szczesna-Skorupa and Kemper (2011), although it is likely isoform-dependent. It has been reported that PGRMC1 is highly expressed in breast and ovary tumors and in cancer cell lines from the colon, thyroid, lung, and cervix (Crudden et al., 2005; Peluso et al., 2008a) . Recently, it has been reported that PGRMC1 is highly expressed in human myometrium during pregnancy and may mediate the relaxation effect on myometrium (Wu et al., 2011) . The changes of PGRMC1 expression under certain physiological conditions might impact on the metabolism of steroids. Meanwhile, little is known about the factors that affect the PGRMC1 expression level in human liver. Further studies are warranted to clarify the physiological significance of PGRMC1 in the modulation of drug-metabolizing P450 in liver.
In conclusion, we found that PGRMC1 decreases the activities of drug-metabolizing P450s
in an isoform-dependent manner. The action was opposite to that for steroid-metabolizing P450s. Thus, PGRMC1 seems to affect P450s depending on their functions. The present study revealed a novel function of PGRMC1 in modulating the drug-metabolizing activity.
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Fig. 3. Kinetic analyses of S-warfarin 7-hydroxylation (A) and diclofenac 4'-hydroxylation (B)
by recombinant CYP2C9 in single or co-expression systems with PGRMC1. The expression systems were constructed using recombinant adenoviruses as described under Material and
Methods. The obtained kinetic parameters are shown in Table 3 . Data are the means ± SD of three independent determinations. MOI, multiplicity of infection. The expression systems were constructed using recombinant adenoviruses as described under
Material and Methods. The obtained kinetic parameters are shown in Table 4 . Data are the means ± SD of three independent determinations. MOI, multiplicity of infection.
This article has not been copyedited and formatted. The final version may differ from this version. S-warfarin 7-hydroxylase activity (at 10 µM substrate concentration), and chlorzoxazone 6-hydroxylase activity (at 500 µM substrate concentration) in the homogenates were measured.
* P < 0.05 and ***P < 0.001. NS, not significant. -56.9 ± 9.1 54.3 ± 4.0 0.96 ± 0.08 5.7 ± 0.9 9.8 ± 1.5 15.9 ± 4.1 1.72 ± 0.03 × 1 53.1 ± 22.3 51.2 ± 5.9 1.07 ± 0.42 10.9 ± 2.2 * 6.5 ± 0.7 * 10.4 ± 7.5 0.60 ± 0.05 * × 2 71.4 ± 14.2 43.4 ± 4.4 * 0.62 ± 0.07 * 11.6 ± 3.8 * 5.0 ± 1.4 * 17.8 ± 11.6 0.44 ± 0.04 * × 4 91.8 ± 12.2 * 37.4 ± 2.7 ** 0.41 ± 0.04 * 12.5 ± 2.1 * 4.1 ± 0.6 ** 16.3 ± 3.1 0.33 ± 0.01 **
The expression systems were constructed using recombinant adenoviruses as described under Materials and Methods. Kinetic parameters were calculated from curves by non-linear regression. Data are mean ± SD of three independent experiments. * P < 0.05 and ** P < 0.01 compared with control by Shirley-Williams' test.
